News

  1. 3 PhD students of the INP participate in the Neuroschool PhD Days 2018

    On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students  were invited to present their work.

    It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.

  2. Vect-Horus announces agreement with Johnson & Johnson innovation

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

  3. Santiago Rivera gave two conferences on Alzheimer's disease

    The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.

    The second conference, in the context of the Conferences Cycle of the Institute of Neurosciences of the University of Barcelona, was entitled “ Membrane type-matrix metalloproteinases are newcomers to the Alzheimer’s field ”  ans was held on November 20th at the School of Pharmacy of the University of Barcelona.

  4. New article from the Neural Degeneration and Plasticity team

    The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R). Our data unveil new mechanistic insights supporting the pro-amyloidogenic role of MT1-MMP based on APP processing and trafficking, and reinforces the idea that MT1-MMP may become a new potential therapeutic target in Alzheimer’s disease. 

  5. 6th French Biacore User Meeting

    Géraldine Ferracci, manager of the Surface Plasmon Resonance unit at INP's Plateform Interactome Neuro-Timone (PINT), gave a talk at the 6th Biacore Users' Meeting. During her presentation untitled "Contribution of the SPR in the study of membrane proteins: from their quantification to the optimization of therapeutic peptide vectors", she stressed the role of this major biophysical technique, played in the therapeutic approaches developed within the INP.

  6. Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

    Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

  7. Details of hotspots seen by STORM
    New article from the NeuroCyto Team: Slow axonal transport of actin via hotspots and trails

    The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon. They generate the assembly of trails, long actin filaments that polymerize along the axon and collapse within seconds.

  8. The INP welcomes Professor Emeritus Jean-Michel SCHERRMANN

    On Friday, November 23, the INP welcomes Professor Emeritus Jean-Michel SCHERRMANN (University of Paris Descartes), for a seminar entitled "Why it is difficult to develop CNS drugs: lack of neuropharmacokinetic considerations?”

    Developing efficient drugs for treating cerebral disorders remains a true challenge. Reducing the duration and cost of preclinical and clinical trials as well as identifying the wrong candidates, as quickly as possible, are key priorities. Such goals require translational research and strong interdisciplinary interactions. 

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

3 PhD students of the INP participate in the Neuroschool PhD Days 2018

On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students  were invited to present their work.

It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.

English

Vect-Horus announces agreement with Johnson & Johnson innovation

Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

Undefined

New article from the Neural Degeneration and Plasticity team

The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R).

Undefined

Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

Undefined

New article from the NeuroCyto Team: Slow axonal transport of actin via hotspots and trails

The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon.

Undefined
Details of hotspots seen by STORM

1st Congress of the 7 CoENs (International Network of Centers of Excellence in Neurodegeneration)

Santiago Rivera represented the INP on the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) held in Montpellier on October 18 and 19, 2018, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. He gave a lecture in the CoEN Pathfinder laureates’ session entitled MT-MMPs at the crossroads of amyloidogenesis and neuroinflammation in Alzheimer's disease.

Undefined

Ludovic Leloup (team cytoskeleton & neurophysiopathology) received a 30 000 € grant from the GEFLUC

The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.

Photo from the GEFLUC

Undefined

Next seminars

25 Jan 2019 14:30

Assemblée Générale du Laboratoire

Faculté de pharmacie de la Timone

1 Feb 2019 14:30

Daniel Bertin - « Immunomonitoring des biothérapies anti-TNF alpha »

Faculté de médecine Nord, salle de conférences, bâtiment E

Daniel Bertin is pharmacist in the Conception and is in the team 5 - Neuro-inflammation and Multiple Sclerosis.

8 Feb 2019 14:30

Santiago Rivera - (Team 1 - Neural Plasticity and Degeneration)

Faculté de pharmacie de la Timone

Santiago Rivera is DR2 and the leader of the team 1 - Neural Plasticity and Degeneration.

Partners